JS Link Inc, formerly DNA Link Inc, is a Korea-based company mainly engaged in the genome analysis business. The Company mainly engages in the research and development of genome analysis services and personal genome analysis service products used for disease prevention, diagnosis, and treatment. The Company also mainly engages in the manufacture and sale of coronavirus disease 2019 (COVID-19) diagnostic kits. In addition, the Company engages in the research and development of â€˜Avatar Mouse,â€™ an anticancer drug efficacy evaluation system using the mouseâ€™s biological system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/07/26	₩34,750.00	-13.66%	200,942
15/07/26	₩40,250.00	+8.93%	257,988
14/07/26	₩36,950.00	0.00%	86,226
13/07/26	₩36,950.00	-5.13%	114,927
10/07/26	₩38,950.00	+4.28%	122,803

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 16/07/2026			5-day change	1st Jan Change
34,750.00 ^KRW	-13.66%		-6.96%	+94.68%

07-07	REalloys Inc. and JS Link Inc. Sign Non-Binding Strategic Letter of Intent to Develop Fully Integrated North American Rare Earth Magnet Platform	CI
07-07	Australia's Lynas, South Korea's JS Link sign deal for Malaysia magnet factory	RE

Market Cap	1,207B 812M 710M 655M 603M 1.14B 78.19B 1.16B 7.83B 3.08B 38.29B 3.05B 2.98B 132B	P/E 2024	-10.5x	P/E 2025	-29.7x
Enterprise Value	1,210B 814M 711M 656M 605M 1.14B 78.37B 1.17B 7.84B 3.09B 38.38B 3.06B 2.99B 132B	EV / Sales 2024	8.93x	EV / Sales 2025	29.6x
Free-Float	70.46%	Yield 2024 *	-	Yield 2025	-

07-07	REalloys Inc. and JS Link Inc. Sign Non-Binding Strategic Letter of Intent to Develop Fully Integrated North American Rare Earth Magnet Platform	CI
07-07	Australia's Lynas, South Korea's JS Link sign deal for Malaysia magnet factory	RE
07-07	Australia's Lynas signs deal with South Korea's JS Link to develop Malaysian magnet factory	RE
06-25	JS Link, Inc. announced that it has received KRW 30 billion in funding from Joosung Sea & Air Co. Ltd	CI
05-15	JS Link, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	JS Link, Inc. announced that it expects to receive KRW 5 billion in funding	CI
05-13	JS Link, Inc. announced that it expects to receive KRW 30 billion in funding	CI
03-23	JS Link, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-03	JS Link, Inc. announced that it has received KRW 20.00000805 billion in funding from Orbitech Co., Ltd., Joosung Sea & Air Co. Ltd	CI
11-14	JS Link, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Malaysia PM says $142 million magnet plant to boost rare earth sector, state media reports	RE
29/10/25	JS Link, Inc. announced that it has received KRW 20.000005568 billion in funding from B & P Joosung Corp.	CI
02/10/25	JS Link, Inc. announced that it has received KRW 12 billion in funding	CI

1 day	-13.66%
1 week	-6.96%
Current month	-7.21%
1 month	-3.74%
3 months	-26.30%
6 months	+74.71%
Current year	+94.68%

JS Link, Inc. Stock

Stocks

A127120

KR7127120004

Biotechnology & Medical Research

Valuation: JS Link, Inc.

Chart: JS Link, Inc.

Latest news : JS Link, Inc.

Press Releases: JS Link, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: JS Link, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	33,950	41,250
1 month	29,350	41,250
Current year	16,230	49,900
1 year	12,500	49,900
3 years	1,775	49,900
5 years	1,775	49,900
10 years	1,775	49,900

Manager	Title	Age	Since
Jun-Young Lee CEO	Chief Executive Officer	58	23/08/2024
Cheol-Gu Sim CEO	Chief Executive Officer	47	20/10/2023
Kenji Gonishi PRN	Corporate Officer/Principal	58	23/08/2024

Director	Title	Age	Since
Cheol-Gu Sim BRD	Director/Board Member	47	20/10/2023
Jun-Young Lee BRD	Director/Board Member	58	23/08/2024
Kenji Gonishi BRD	Director/Board Member	58	23/08/2024

Date	Insider	Type	Quantity	% Market Cap.
19/11/25	Jin-soo Park	Buy	1,500	0.0047%
17/11/25	Jin-soo Park	Buy	5,000	0.0157%
04/11/25	Jin-soo Park	Buy	87,138	0.2742%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JS LINK, INC.	-13.66%	-6.96%	+155.14%	+891.44%	815M
LONZA GROUP AG	-1.29%	-2.54%	-0.35%	+4.30%	49.7B
REVOLUTION MEDICINES, INC.	+3.90%	-2.60%	+384.79%	+598.27%	38.09B
BEONE MEDICINES AG	-1.70%	+3.03%	+11.77%	+58.93%	35.29B
IQVIA HOLDINGS INC.	-2.01%	-1.30%	+30.02%	-6.71%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	+0.46%	-5.24%	-	-	16.14B
MEDPACE HOLDINGS, INC.	-0.04%	+0.42%	+70.80%	+121.10%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+2.15%	+16.24%	+19.12%	13.89B
ICON PUBLIC LIMITED COMPANY	0.00%	+0.73%	+18.02%	-30.96%	13.02B
Average	-1.34%	-1.59%	+76.76%	+186.99%	24.47B
Weighted average by Cap.	-0.19%	-0.68%	+78.35%	+122.71%

	2024	2025
Net sales	15.91B 10.7M 9.35M 8.63M 7.95M 14.99M 1.03B 15.32M 103M 40.56M 505M 40.18M 39.29M 1.74B	19.32B 12.99M 11.35M 10.48M 9.66M 18.2M 1.25B 18.6M 125M 49.25M 613M 48.78M 47.71M 2.11B
Net income	-10.8B -7.26M -6.35M -5.86M -5.4M -10.18M -700M -10.4M -70.02M -27.54M -343M -27.28M -26.68M -1.18B	-16.45B -11.06M -9.66M -8.92M -8.22M -15.49M -1.07B -15.84M -107M -41.93M -522M -41.53M -40.62M -1.8B
Net Debt	14.39B 9.68M 8.46M 7.81M 7.19M 13.56M 932M 13.86M 93.29M 36.69M 456M 36.35M 35.55M 1.57B	2.88B 1.94M 1.69M 1.56M 1.44M 2.71M 187M 2.78M 18.68M 7.35M 91.39M 7.28M 7.12M 315M